Arrow
Arrow
Slider

Premaitha Health PLC
(“Premaitha” or the “Company”)

Premaitha to offer NIPT in South Africa

Manchester, UK – 19 September 2017: Premaitha Health PLC (AIM: NIPT), a leading international molecular diagnostics group focused on non-invasive prenatal testing, announces that it has signed an agreement with Ampath group, practising as Drs Du Buisson, Kramer, Swart, Bouwer Inc. (“Ampath”) to offer the Company’s IONA® test in South Africa, where the Company has appointed Barker Medical Pty Ltd (“Barker”) as its distributor.

Ampath will install a dedicated non-invasive prenatal testing (“NIPT”) centre at its national reference laboratory in Gauteng province, servicing major cities, including Johannesburg. Premaitha believes Ampath will be among the first laboratories in South Africa to offer a CE-IVD accredited NIPT system and will act as a hub, extending services to its national network of clinics and hospitals across the country.

Premaitha's IONA® test estimates the risk of a fetus being affected with Down's syndrome or other genetic conditions. The test is performed on a maternal blood sample, containing traces of fetal DNA, which is then analysed using next generation DNA sequencing technology. The test is highly accurate and significantly reduces the number of women who are unnecessarily subjected to risky, invasive follow up procedures to diagnose Down's syndrome and other genetic conditions.

Dr Stephen Little, CEO of Premaitha Health, commented: “We are delighted to announce that the IONA® test will be made available to women in South Africa, expanding Premaitha’s footprint to another continent. South Africa is another strategically important region as we build our global footprint and further de-risk our business.”

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

For more information, please contact:    

Premaitha Health PLC
Dr Stephen Little, Chief Executive Officer
Barry Hextall, Chief Financial Officer
Joanne Cross, Head of Marketing
This email address is being protected from spambots. You need JavaScript enabled to view it.
Tel: +44 (0)161 667 1053
 
Cairn Financial Advisers LLP (NOMAD)
Liam Murray / James Caithie
Tel: +44 (0)20 7213 0880

finnCap (Broker)
Adrian Hargrave / Scott Mathieson (Corporate Finance)
Tony Quirke (Corporate Broking)    
Tel: +44 (0)20 7220 0500

Vigo Communications
Ben Simons / Fiona Henson / Antonia Pollock
This email address is being protected from spambots. You need JavaScript enabled to view it.
Tel: +44 (0)20 7830 9700

About Premaitha

Premaitha is an international molecular diagnostics group which uses the latest advances in DNA analysis technology to develop safer, faster and regulatory approved genetic screening tests. The Group’s primary focus is on non-invasive prenatal tests (NIPT) for pregnant women - an emerging, multi-billion dollar global market.

Premaitha’s IONA® test was launched in 2015 as the first CE-IVD NIPT test in Europe. It enables laboratories and healthcare practitioners to offer a complete CE-marked NIPT system in-house. The IONA® test is performed on a maternal blood sample – which contains traces of fetal DNA – and estimates the risk of a fetus being affected with Down’s syndrome or other genetic conditions.

Unlike existing prenatal screening methods, due to its high level of accuracy, the IONA® test can significantly reduce the number of women subjected to unnecessary invasive follow up diagnostic procedures, such as amniocentesis, which are costly, resource intensive and carry a risk of miscarriage.

In March 2017, Premaitha acquired Yourgene Bioscience, a specialist next generation sequencing and bioinformatics company based in Taiwan, with its own NIPT screening test that operates on the same Thermo Fisher next-generation sequencing platform as Premaitha’s IONA® test. Yourgene brings significant benefits to the Group through expanded market access in Asia – the world's fastest growing NIPT market – as well as opportunities for cross-selling and the ability to jointly develop expanded test content both within NIPT and beyond.

Premaitha is headquartered in Manchester, England, with Yourgene offices in Taipei and Singapore. Its shares trade on the AIM market of the London Stock Exchange (AIM: NIPT). For further information, please visit www.premaitha.com. Follow us on twitter @PremaithaHealth.

  • 29 December 2017 - Half Year Results +

    Premaitha Health PLC
    (“Premaitha”, the “Company” or the “Group”)

    Half year results

    Manchester, UK – 29 December 2017: Premaitha Health PLC (AIM: NIPT), a leading molecular diagnostics group with a primary focus on the commercialisation of its non-invasive prenatal testing (“NIPT”) technology, announces half year results for the six months ended 30 September 2017.

    Financial highlights
    •    Revenues increased by 87% to £2.7m (H1 2016/17: £1.5m)
    •    Test volumes doubled to over 22,000 (H1 2016/17:

    Read More
  • 11 December 2017 - Premaitha secures four further laboratories in Europe +

    Premaitha Health PLC
    (“Premaitha” or the “Company”)

    Premaitha secures four further laboratories in Europe

    Manchester, UK – 11 December 2017: Premaitha Health PLC (AIM: NIPT), a leading international molecular diagnostics group focused on non-invasive prenatal testing (NIPT), announces further expansion of its European customer base, with four new laboratories added.

    The laboratories are situated across three EU countries. The Company’s European distributors secured three of the laboratories, with one laboratory having been contracted directly by

    Read More
  • 01 December 2017 - Premaitha CEO Wins Bionow Outstanding Contribution Award +

    Premaitha CEO Wins Bionow Outstanding Contribution Award

    Steve Little

    Manchester, UK – 1 December 2017: Premaitha Health PLC (AIM: NIPT), a leading international molecular diagnostics group focused on non-invasive prenatal testing (NIPT), is proud to announce that its CEO, Dr Stephen Little, last night received Bionow’s Outstanding Contribution award in recognition of his “significant contribution to the biomedical sector.”

    Bionow is an organisation which supports business growth, competitiveness and innovation within the biomedical and life science sectors

    Read More
  • 27 November 2017 - Middle East laboratory network expansion +

    Premaitha Health PLC
    (“Premaitha” or the “Company”)

    Middle East laboratory network expansion

    Manchester, UK – 27 November 2017: Premaitha Health PLC (AIM: NIPT), a leading international molecular diagnostics group focused on non-invasive prenatal testing (NIPT), announces further expansion of its Middle Eastern customer base, with four new laboratories having been signed up in the region.

    Premaitha’s Middle Eastern distributors have secured four new laboratories seeking to offer the IONA ® test to their respective population

    Read More
  • 23 November 2017 - Premaitha signs new partner to offer NIPT solution in East Asia +

    Premaitha Health plc
    (“Premaitha” or the “Company”)

    Premaitha signs new partner to offer NIPT solution in East Asia

    Manchester, UK – 23 November 2017: Premaitha Health plc (AIM: NIPT), a leading international molecular diagnostics group focused on non-invasive prenatal testing (“NIPT”), announces that it has signed an agreement with a new laboratory partner (the “Partner”) to offer an NIPT screening solution in a new East Asian territory (the “Territory”) for Premaitha.  

    The Partner is

    Read More
  • 21 November 2017 - Litigation First Instance Judgment +

    Premaitha Health plc
    (“Premaitha” or the “Company” or the “Group”)

    Litigation First Instance Judgment

    Manchester, UK – 21 November 2017: Premaitha Health plc (AIM: NIPT), a leading international molecular diagnostics group focused on non-invasive prenatal testing (“NIPT”), announces details of a legal judgment handed down today.

    The UK High Court has today delivered its first instance judgment (the Judgment) in relation to the ongoing dispute with Illumina Inc and others concerning three UK patent families,

    Read More
  • 13 October 2017 - Commercial progress in the Middle East +

    Premaitha Health PLC
    (“Premaitha” or the “Company”)

    Commercial progress in the Middle East

    Manchester, UK – 13 October 2017: Premaitha Health PLC (AIM: NIPT), a leading international molecular diagnostics group focused on non-invasive prenatal testing (NIPT), announces further commercial progress in the Middle East, where several new contracts have been signed via the Company’s regional distribution network.

    Premaitha has secured contracts with three additional laboratories in the region including in the UAE and Saudi Arabia,

    Read More
  • 29 September 2017 - Full year results to 31 March 2017 and half-year trading update +

    Issued on behalf of Premaitha Health plc
    Manchester, UK: Friday, 29 Sept 2017

    Premaitha Health PLC
    (“Premaitha,” the “Company” or the “Group”)

    Full year results to 31 March 2017 and half-year trading update

    Manchester, UK – 29 September 2017: Premaitha (AIM: NIPT), a leading international molecular diagnostics group focused on non-invasive prenatal testing (“NIPT”), announces its full year results for the twelve months ended 31 March 2017; and provides an update on trading performance in

    Read More
  • 19 September 2017 - Premaitha to offer NIPT in South Africa +

    Premaitha Health PLC
    (“Premaitha” or the “Company”)

    Premaitha to offer NIPT in South Africa

    Manchester, UK – 19 September 2017: Premaitha Health PLC (AIM: NIPT), a leading international molecular diagnostics group focused on non-invasive prenatal testing, announces that it has signed an agreement with Ampath group, practising as Drs Du Buisson, Kramer, Swart, Bouwer Inc. (“Ampath”) to offer the Company’s IONA ® test in South Africa, where the Company has appointed Barker Medical Pty Ltd

    Read More
  • 7 September 2017 - Further patent infringement claims received from Illumina & Sequenom +

    Premaitha Health plc
    (“Premaitha” or the “Company”)

    Further patent infringement claims received from Illumina & Sequenom

    Manchester, UK – 7 September 2017: Premaitha Health plc (AIM: NIPT) announces that it has today received notification from Illumina and Sequenom that a further claim for patent infringement has been filed in the High Court of Justice in London.

    Premaitha is a leading international molecular diagnostics group focused on non-invasive prenatal testing (“NIPT”) and has been robustly defending

    Read More
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
Pregnant lady sitting at table with Laptop

Investor Relations
Ben Simons / Fiona Henson
Vigo Communications
180 Piccadilly
London W1J 9HF
premaitha@vigocomms.com
T : +44 (0) 20 7830 9700

Two business people looking at computer screen